###begin article-title 0
Fas Ligand Expression in Lynch Syndrome-Associated Colorectal Tumours
###end article-title 0
###begin p 1
###xml 355 363 <span type="species:ncbi:9606">patients</span>
Fas Ligand (FasL) expression by cancer cells may contribute to tumour immune escape via the Fas counterattack against tumour-infiltrating lymphocytes (TILs). Whether this plays a role in colorectal carcinogenesis in Lynch syndrome was examined studying FasL expression, tumour cell apoptosis and number of TILs in colorectal neoplasms from Lynch syndrome patients (50 adenomas, 20 carcinomas) compared with sporadic cases (69 adenomas, 52 carcinomas). FasL expression was observed in 94% of Lynch syndrome adenomas and in all carcinomas. FasL expression patterns and apoptotic indices were similar in Lynch syndrome-associated neoplasms and sporadic cases. The number of TILs was higher in Lynch syndrome neoplasms than in sporadic cases. There were no correlations between FasL expression and tumour cell apoptosis or number of TILs in Lynch syndrome-associated neoplasms. So, FasL expression is an early event in Lynch syndrome and sporadic colorectal carcinogenesis, but not related to TIL number. Taken together, our data do not support a role for the Fas counterattack in colorectal carcinogenesis in Lynch syndrome.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 881 882 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1014 1015 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
Lynch syndrome (LS), or hereditary nonpolyposis colorectal cancer (HNPCC), is characterised by an autosomal dominant inheritance of early-onset colorectal cancer and an increased risk of other cancers, in particular cancer of the endometrium [1]. LS is caused by germline mutations in a mismatch repair gene, mostly hMLH1, hMSH2 and hMSH6 [1]. These genes encode proteins involved in DNA repair. Failure of the DNA mismatch repair machinery to repair errors occurring during DNA replication leads to increased length variation of simple, repetitive sequences distributed throughout the genome, so-called microsatellite instability (MSI). An international set of markers is developed to test for MSI. Tumours are scored MSI-high if at least 30% of the markers show instability, MSI-low if less than 30% show instability, or MS-stable (MSS) if none of the markers shows instability [2]. The MSI-H phenotype is found in up to 92% of colorectal cancers associated with LS and in 10-15% of sporadic colorectal cancers [1].
###end p 4
###begin p 5
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 644 647 644 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAX</italic>
###xml 652 661 652 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">caspase 5</italic>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 807 808 807 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
Dysfunction of one of the mismatch repair genes results in a rapid accumulation of genetic alterations in susceptible genes, including genes involved in growth suppression, apoptosis and signal transduction [1]. These alterations contribute to an accelerated adenoma-carcinoma sequence in LS compared to sporadic cancer. This is illustrated by the relative frequent occurrence of interval cancers between regular surveillance colonoscopies [3, 4]. In addition, LS adenomas frequently harbour a villous component and high-grade dysplasia, both markers of increased cancer risk [5, 6]. Among the genes that are targeted in the setting of MSI are BAX and caspase 5, suggesting that disturbances in apoptosis regulation may be important as a mechanism behind the accelerated colorectal carcinogenesis in LS [7, 8].
###end p 5
###begin p 6
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1202 1204 1202 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 678 683 <span type="species:ncbi:9606">human</span>
###xml 1284 1292 <span type="species:ncbi:9606">patients</span>
###xml 1562 1570 <span type="species:ncbi:9606">patients</span>
Apoptosis can be either initiated by the cell itself or by certain external stimuli. These external stimuli may induce apoptosis by targeting one of two pathways [7]. The 'extrinsic' pathway is initiated by triggering cell death receptors on the cell surface, leading to activation of the intracellular apoptotic machinery. The 'intrinsic' pathway of apoptosis is initiated via the mitochondria by cellular stress, such as chemotherapeutic drugs and radiation. Fas is a protein of the tumour necrosis factor (TNF) receptor superfamily, known to induce apoptosis through the extrinsic pathway in sensitive cells by binding to its natural ligand, Fas Ligand (FasL). In the normal human colon, all epithelial cells express Fas, but not FasL [9]. In contrast, many colorectal carcinomas and some adenomas show FasL expression [10-13]. It has been hypothesized that FasL expression in tumour cells might enable these cells to evade immune destruction by inducing apoptosis in tumour-infiltrating lymphocytes (TILs), a concept which has become known as the Fas counter-attack [14]. In a previous study, FasL expression was reported to be higher in MSI-H colorectal cancers compared to MSI-L and MSS cancers [15]. To date, FasL expression has not been examined in colorectal tumours from LS patients. We hypothesized that a diminished Fas counterattack between LS and sporadic colorectal tumours play a role as a mechanism to explain the difference in carcinogenesis. Therefore, FasL expression, tumour cell apoptosis and number of TILs in colorectal neoplasms from LS patients in comparison with sporadic cases were studied.
###end p 6
###begin title 7
Materials and Methods
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 8
###begin p 9
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lynch Syndrome</bold>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1</italic>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2</italic>
###xml 579 584 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH6</italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
###xml 773 781 <span type="species:ncbi:9606">patients</span>
Lynch Syndrome At the University Medical Centre Groningen, patients with a germline mismatch repair gene mutation and/or fulfilling the Amsterdam II criteria undergo colonoscopy every 1-2years starting at the age of 25years, according to the current surveillance guidelines [1]. All colorectal adenomas and carcinomas removed in these patients over a period of 23years with sufficient material available to allow serial sectioning for immunohistochemistry were selected for this study. In total, 20 carcinomas were examined, 17 from proven mutation carriers (8 hMLH1, 7 hMSH2, 2 hMSH6), as determined by sequencing of genomic DNA, and three from patients with a family history fulfilling the Amsterdam II criteria. Fifty adenomas, 23 from proven mutation carriers, 27 from patients with a family history fulfilling the Amsterdam II criteria, were analyzed.
###end p 9
###begin p 10
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic cases</bold>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 834 835 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1458 1460 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
Sporadic cases The control group consisted of sporadic carcinomas from a previously reported cohort of 500 patients with stage III colon cancer [16]. From this cohort, in which MSI analysis has been performed, we selected all MSI-H tumours (n = 26) and randomly 26 MSS tumours. MSI-H tumours were included to determine possible differences between sporadic MSI-H tumours and LS-associated tumours which also are characterized by the MSI-H phenotype. None of the 26 patients with a MSI-H tumour was known with a MMR gene mutation or had a family history fulfilling the Amsterdam II criteria, so these were considered truly sporadic cases. Sporadic adenomas of which sufficient material was available to allow serial sectioning for immunohistochemical staining were selected from a previously described series [17] as control adenomas (n = 69).Histologic classifications were carried out on haematoxylin and eosin stained slides. The morphological classification of the carcinomas and adenomas was conducted according to the World Health Organization (WHO) criteria [18]. Adenocarcinomas were graded into well, moderately and poorly differentiated. For statistical purposes, tumours with good and moderate differentiation were compared with tumours with poor differentiation. From adenomas, the circumferential size was measured, and the severity of dysplasia was expressed as low- or high-grade. Adenomas were classified as tubular, tubulovillous or villous [18]. For statistical purposes, tubulovillous and villous adenomas were taken together.
###end p 10
###begin title 11
Immunohistochemistry
###end title 11
###begin p 12
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1328 1330 1328 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 674 680 <span type="species:ncbi:9986">rabbit</span>
###xml 686 690 <span type="species:ncbi:9925">goat</span>
For immunohistochemical staining for FasL, sections were deparaffinized in xylene, rehydrated through decreasing concentrations of alcohol and finally in phosphate-buffered saline. For antigen retrieval, slides were subjected to steam-heat for 30min, using a commercially available steamer. After washing with PBS, sections were incubated with avidin and biotin blocking solutions (Vector Laboratories, Burlingame, CA, USA), followed by incubation for 1h at room temperature with a monoclonal anti-FasL antibody (MAb33, Transduction Laboratories, Lexington, KY, USA) in a 1:300 dilution. After washing with PBS, slides were incubated with a 1:300 dilution of a biotinylated rabbit-anti-goat antibody (DAKO, Glostrup, Denmark), followed by addition of streptavidin-conjugated peroxidase (DAKO). Peroxidase activity was visualized with diaminobenzidine. Counterstaining was performed with haematoxylin. As negative controls, slides were immunostained in the absence of the primary antibody, and in these cases no immunostaining was detected. Evaluation of staining was performed by two independent investigators, without knowledge of the histopathological data. The percentage of positive cells was estimated and scored on a semiquantitative scale as (1) 0-25%, (2) 26-50%, (3) 51-75%, (4) 76-100%, in accordance with others [14, 15].
###end p 12
###begin p 13
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 78 84 <span type="species:ncbi:10090">murine</span>
Apoptosis in epithelial cells was determined by immunohistochemistry with the murine monoclonal antibody M30 (Boehringer Mannheim, Mannhein, Germany), which reacts with a cleavage product of cytokeratin 18, released by activated caspase [19]. The immunoreactivity of the M30 antibodies is confined to the cytoplasm of apoptotic cells and is present during early apoptosis [20]. M30 staining has been shown to correlate well with the gold standard of morphological criteria [17]. Staining procedures for M30 were performed as described before [17]. Apoptosis was assessed in at least 1,000 tumour cells and expressed as a percentage of the total number of cells counted (apoptotic index). M30 positivity was identified as brown cytoplasmic staining.
###end p 13
###begin p 14
###xml 287 293 <span type="species:ncbi:9986">rabbit</span>
###xml 299 304 <span type="species:ncbi:10090">mouse</span>
###xml 363 367 <span type="species:ncbi:9925">goat</span>
###xml 373 379 <span type="species:ncbi:9986">rabbit</span>
The presence of TILs was assessed using a monoclonal antibody against CD8. Antigen retrieval was performed by immersing slides in 1mM EDTA buffer (pH 8.0) and heating in a microwave oven for 8min. The primary antibody (DAKO) was applied in a 1:50 solution for 1h followed by a secondary rabbit-anti-mouse antibody conjugated with peroxidase (DAKO) and a tertiary goat-anti-rabbit peroxidase-conjugated antibody.
###end p 14
###begin p 15
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
For each tumour, the number of intraepithelial CD8+ cells was determined in ten high power fields (400 x magnification), in accordance with other studies [15, 21, 22]. TILs were defined as intraepithelial rather than peri-tumoural or stromal lymphocytes.
###end p 15
###begin title 16
Statistical Analysis
###end title 16
###begin p 17
Statistical significance of differences between LS and sporadic cases was tested using the Mann-Whitney test for continuous variables and chi-square tests for discontinuous variables. To test the relationship between increasing FasL expression and continuous variables as apoptotic index and CD8 counts, the Wilcoxon rank sum test was used. P-values <0.05 were considered significant. SPSS for Windows software (SPSS Inc., Chicago, IL, USA) was used.
###end p 17
###begin title 18
Results
###end title 18
###begin title 19
Tumour Characteristics
###end title 19
###begin p 20
###xml 59 60 59 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 640 647 640 647 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 647 681 647 681 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">Patient and tumour characteristics</p>
###xml 647 681 647 681 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21">Patient and tumour characteristics</p></caption>
###xml 681 682 681 682 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 682 690 682 690 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Adenomas</th>
###xml 690 700 690 700 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Carcinomas</th>
###xml 700 700 700 700 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 681 700 681 700 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="2">Carcinomas</th><th/></tr>
###xml 700 702 700 702 <th xmlns:xlink="http://www.w3.org/1999/xlink">LS</th>
###xml 702 710 702 710 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic</th>
###xml 710 712 710 712 <th xmlns:xlink="http://www.w3.org/1999/xlink">LS</th>
###xml 712 724 712 724 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic MSS</th>
###xml 724 738 724 738 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic MSI-H</th>
###xml 700 738 700 738 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr>
###xml 738 739 738 739 <th xmlns:xlink="http://www.w3.org/1999/xlink">n</th>
###xml 739 741 739 741 <th xmlns:xlink="http://www.w3.org/1999/xlink">50</th>
###xml 741 743 741 743 <th xmlns:xlink="http://www.w3.org/1999/xlink">69</th>
###xml 743 745 743 745 <th xmlns:xlink="http://www.w3.org/1999/xlink">20</th>
###xml 745 747 745 747 <th xmlns:xlink="http://www.w3.org/1999/xlink">26</th>
###xml 747 749 747 749 <th xmlns:xlink="http://www.w3.org/1999/xlink">26</th>
###xml 738 749 738 749 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr>
###xml 681 749 681 749 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="2">Carcinomas</th><th/></tr><tr><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr><tr><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr></thead>
###xml 749 757 749 757 <td xmlns:xlink="http://www.w3.org/1999/xlink">Male (%)</td>
###xml 757 759 757 759 <td xmlns:xlink="http://www.w3.org/1999/xlink">48</td>
###xml 759 761 759 761 <td xmlns:xlink="http://www.w3.org/1999/xlink">30</td>
###xml 761 763 761 763 <td xmlns:xlink="http://www.w3.org/1999/xlink">85</td>
###xml 763 765 763 765 <td xmlns:xlink="http://www.w3.org/1999/xlink">73</td>
###xml 765 767 765 767 <td xmlns:xlink="http://www.w3.org/1999/xlink">69</td>
###xml 749 767 749 767 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Male (%)</td><td>48</td><td>30</td><td>85</td><td>73</td><td>69</td></tr>
###xml 767 791 767 791 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age in yrs (mean, range)</td>
###xml 791 801 791 801 <td xmlns:xlink="http://www.w3.org/1999/xlink">49 (30&#8211;67)</td>
###xml 801 811 801 811 <td xmlns:xlink="http://www.w3.org/1999/xlink">66 (28&#8211;89)</td>
###xml 811 821 811 821 <td xmlns:xlink="http://www.w3.org/1999/xlink">54 (31&#8211;77)</td>
###xml 821 831 821 831 <td xmlns:xlink="http://www.w3.org/1999/xlink">59 (40&#8211;75)</td>
###xml 831 841 831 841 <td xmlns:xlink="http://www.w3.org/1999/xlink">60 (26&#8211;76)</td>
###xml 767 841 767 841 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age in yrs (mean, range)</td><td>49 (30&#8211;67)</td><td>66 (28&#8211;89)</td><td>54 (31&#8211;77)</td><td>59 (40&#8211;75)</td><td>60 (26&#8211;76)</td></tr>
###xml 841 865 841 865 <td xmlns:xlink="http://www.w3.org/1999/xlink">Size in mm (mean, range)</td>
###xml 865 875 865 875 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.9 (2&#8211;30)</td>
###xml 875 886 875 886 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.2 (3&#8211;45)</td>
###xml 886 886 886 886 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 886 886 886 886 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 886 886 886 886 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 841 886 841 886 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Size in mm (mean, range)</td><td>6.9 (2&#8211;30)</td><td>10.2 (3&#8211;45)</td><td/><td/><td/></tr>
###xml 886 911 886 911 <td xmlns:xlink="http://www.w3.org/1999/xlink">Proximal localisation (%)</td>
###xml 911 913 911 913 <td xmlns:xlink="http://www.w3.org/1999/xlink">42</td>
###xml 913 915 913 915 <td xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 915 917 915 917 <td xmlns:xlink="http://www.w3.org/1999/xlink">65</td>
###xml 917 919 917 919 <td xmlns:xlink="http://www.w3.org/1999/xlink">39</td>
###xml 919 921 919 921 <td xmlns:xlink="http://www.w3.org/1999/xlink">81</td>
###xml 886 921 886 921 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Proximal localisation (%)</td><td>42</td><td>26</td><td>65</td><td>39</td><td>81</td></tr>
###xml 921 930 921 930 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="6">Pathology</td>
###xml 921 930 921 930 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="6">Pathology</td></tr>
###xml 930 941 930 941 <td xmlns:xlink="http://www.w3.org/1999/xlink">Tubular (%)</td>
###xml 941 943 941 943 <td xmlns:xlink="http://www.w3.org/1999/xlink">54</td>
###xml 943 945 943 945 <td xmlns:xlink="http://www.w3.org/1999/xlink">54</td>
###xml 945 945 945 945 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 945 945 945 945 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 945 945 945 945 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 930 945 930 945 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Tubular (%)</td><td>54</td><td>54</td><td/><td/><td/></tr>
###xml 945 969 945 969 <td xmlns:xlink="http://www.w3.org/1999/xlink">High-grade dysplasia (%)</td>
###xml 969 971 969 971 <td xmlns:xlink="http://www.w3.org/1999/xlink">46</td>
###xml 971 973 971 973 <td xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 973 973 973 973 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 973 973 973 973 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 973 973 973 973 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 945 973 945 973 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>High-grade dysplasia (%)</td><td>46</td><td>26</td><td/><td/><td/></tr>
###xml 973 997 973 997 <td xmlns:xlink="http://www.w3.org/1999/xlink">Poor differentiation (%)</td>
###xml 997 997 997 997 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 997 997 997 997 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 997 999 997 999 <td xmlns:xlink="http://www.w3.org/1999/xlink">25</td>
###xml 999 1001 999 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink">12</td>
###xml 1001 1003 1001 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink">15</td>
###xml 973 1003 973 1003 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Poor differentiation (%)</td><td/><td/><td>25</td><td>12</td><td>15</td></tr>
###xml 749 1003 749 1003 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Male (%)</td><td>48</td><td>30</td><td>85</td><td>73</td><td>69</td></tr><tr><td>Age in yrs (mean, range)</td><td>49 (30&#8211;67)</td><td>66 (28&#8211;89)</td><td>54 (31&#8211;77)</td><td>59 (40&#8211;75)</td><td>60 (26&#8211;76)</td></tr><tr><td>Size in mm (mean, range)</td><td>6.9 (2&#8211;30)</td><td>10.2 (3&#8211;45)</td><td/><td/><td/></tr><tr><td>Proximal localisation (%)</td><td>42</td><td>26</td><td>65</td><td>39</td><td>81</td></tr><tr><td colspan="6">Pathology</td></tr><tr><td>Tubular (%)</td><td>54</td><td>54</td><td/><td/><td/></tr><tr><td>High-grade dysplasia (%)</td><td>46</td><td>26</td><td/><td/><td/></tr><tr><td>Poor differentiation (%)</td><td/><td/><td>25</td><td>12</td><td>15</td></tr></tbody>
###xml 681 1003 681 1003 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="2">Carcinomas</th><th/></tr><tr><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr><tr><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr></thead><tbody><tr><td>Male (%)</td><td>48</td><td>30</td><td>85</td><td>73</td><td>69</td></tr><tr><td>Age in yrs (mean, range)</td><td>49 (30&#8211;67)</td><td>66 (28&#8211;89)</td><td>54 (31&#8211;77)</td><td>59 (40&#8211;75)</td><td>60 (26&#8211;76)</td></tr><tr><td>Size in mm (mean, range)</td><td>6.9 (2&#8211;30)</td><td>10.2 (3&#8211;45)</td><td/><td/><td/></tr><tr><td>Proximal localisation (%)</td><td>42</td><td>26</td><td>65</td><td>39</td><td>81</td></tr><tr><td colspan="6">Pathology</td></tr><tr><td>Tubular (%)</td><td>54</td><td>54</td><td/><td/><td/></tr><tr><td>High-grade dysplasia (%)</td><td>46</td><td>26</td><td/><td/><td/></tr><tr><td>Poor differentiation (%)</td><td/><td/><td>25</td><td>12</td><td>15</td></tr></tbody></table>
###xml 640 1003 640 1003 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="21">Patient and tumour characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="2">Carcinomas</th><th/></tr><tr><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr><tr><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr></thead><tbody><tr><td>Male (%)</td><td>48</td><td>30</td><td>85</td><td>73</td><td>69</td></tr><tr><td>Age in yrs (mean, range)</td><td>49 (30&#8211;67)</td><td>66 (28&#8211;89)</td><td>54 (31&#8211;77)</td><td>59 (40&#8211;75)</td><td>60 (26&#8211;76)</td></tr><tr><td>Size in mm (mean, range)</td><td>6.9 (2&#8211;30)</td><td>10.2 (3&#8211;45)</td><td/><td/><td/></tr><tr><td>Proximal localisation (%)</td><td>42</td><td>26</td><td>65</td><td>39</td><td>81</td></tr><tr><td colspan="6">Pathology</td></tr><tr><td>Tubular (%)</td><td>54</td><td>54</td><td/><td/><td/></tr><tr><td>High-grade dysplasia (%)</td><td>46</td><td>26</td><td/><td/><td/></tr><tr><td>Poor differentiation (%)</td><td/><td/><td>25</td><td>12</td><td>15</td></tr></tbody></table></table-wrap>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 78 85 <span type="species:ncbi:9606">patient</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
Patient and tumour characteristics are summarized in Table 1. Inherent to the patient groups, several differences were observed between groups. Mean age of LS patients at the time of adenoma removal was lower than for those with sporadic disease (p < 0.0001). LS-associated adenomas were smaller (p = 0.002), more often containing high-grade dysplasia (p < 0.01) and more often proximally localized (p < 0.05), i.e. proximal to the splenic flexure, compared with their sporadic counterparts. LS-associated carcinomas and MSI-H sporadic carcinomas were more often localized in the proximal colon compared to sporadic MSS cases, (p < 0.001). Table 1Patient and tumour characteristics AdenomasCarcinomasLSSporadicLSSporadic MSSSporadic MSI-Hn5069202626Male (%)4830857369Age in yrs (mean, range)49 (30-67)66 (28-89)54 (31-77)59 (40-75)60 (26-76)Size in mm (mean, range)6.9 (2-30)10.2 (3-45)Proximal localisation (%)4226653981PathologyTubular (%)5454High-grade dysplasia (%)4626Poor differentiation (%)251215
###end p 20
###begin p 21
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient and tumour characteristics
###end p 21
###begin title 22
FasL Expression in LS and Sporadic Colorectal Neoplasms
###end title 22
###begin p 23
###xml 41 42 41 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 566 573 566 573 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 573 707 573 707 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">FasL expression, epithelial apoptosis (expressed as apoptotic index AI) and TILs in LS and sporadic colorectal adenomas and carcinomas</p>
###xml 573 707 573 707 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">FasL expression, epithelial apoptosis (expressed as apoptotic index AI) and TILs in LS and sporadic colorectal adenomas and carcinomas</p></caption>
###xml 707 708 707 708 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 708 716 708 716 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Adenomas</th>
###xml 716 726 716 726 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Carcinomas</th>
###xml 707 726 707 726 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="3">Carcinomas</th></tr>
###xml 726 728 726 728 <th xmlns:xlink="http://www.w3.org/1999/xlink">LS</th>
###xml 728 736 728 736 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic</th>
###xml 736 738 736 738 <th xmlns:xlink="http://www.w3.org/1999/xlink">LS</th>
###xml 738 750 738 750 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic MSS</th>
###xml 750 764 750 764 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sporadic MSI-H</th>
###xml 726 764 726 764 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr>
###xml 764 765 764 765 <th xmlns:xlink="http://www.w3.org/1999/xlink">n</th>
###xml 765 767 765 767 <th xmlns:xlink="http://www.w3.org/1999/xlink">50</th>
###xml 767 769 767 769 <th xmlns:xlink="http://www.w3.org/1999/xlink">69</th>
###xml 769 771 769 771 <th xmlns:xlink="http://www.w3.org/1999/xlink">20</th>
###xml 771 773 771 773 <th xmlns:xlink="http://www.w3.org/1999/xlink">26</th>
###xml 773 775 773 775 <th xmlns:xlink="http://www.w3.org/1999/xlink">26</th>
###xml 764 775 764 775 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr>
###xml 707 775 707 775 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="3">Carcinomas</th></tr><tr><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr><tr><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr></thead>
###xml 775 788 775 788 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;n FasL + (%)</td>
###xml 788 795 788 795 <td xmlns:xlink="http://www.w3.org/1999/xlink">47 (94)</td>
###xml 795 802 795 802 <td xmlns:xlink="http://www.w3.org/1999/xlink">64 (93)</td>
###xml 802 810 802 810 <td xmlns:xlink="http://www.w3.org/1999/xlink">20 (100)</td>
###xml 810 818 810 818 <td xmlns:xlink="http://www.w3.org/1999/xlink">26 (100)</td>
###xml 818 826 818 826 <td xmlns:xlink="http://www.w3.org/1999/xlink">26 (100)</td>
###xml 775 826 775 826 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;n FasL + (%)</td><td>47 (94)</td><td>64 (93)</td><td>20 (100)</td><td>26 (100)</td><td>26 (100)</td></tr>
###xml 826 832 826 832 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;0&#8211;25%</td>
###xml 832 839 832 839 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (34)</td>
###xml 839 846 839 846 <td xmlns:xlink="http://www.w3.org/1999/xlink">35 (51)</td>
###xml 846 852 846 852 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 (15)</td>
###xml 852 857 852 857 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (8)</td>
###xml 857 863 857 863 <td xmlns:xlink="http://www.w3.org/1999/xlink">4 (15)</td>
###xml 826 863 826 863 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;0&#8211;25%</td><td>17 (34)</td><td>35 (51)</td><td>3 (15)</td><td>2 (8)</td><td>4 (15)</td></tr>
###xml 863 870 863 870 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;26&#8211;50%</td>
###xml 870 875 870 875 <td xmlns:xlink="http://www.w3.org/1999/xlink">4 (8)</td>
###xml 875 881 875 881 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (13)</td>
###xml 881 886 881 886 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (5)</td>
###xml 886 891 886 891 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (4)</td>
###xml 891 896 891 896 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 (8)</td>
###xml 863 896 863 896 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;26&#8211;50%</td><td>4 (8)</td><td>9 (13)</td><td>1 (5)</td><td>1 (4)</td><td>2 (8)</td></tr>
###xml 896 903 896 903 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;51&#8211;75%</td>
###xml 903 909 903 909 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (18)</td>
###xml 909 916 909 916 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 (14)</td>
###xml 916 922 916 922 <td xmlns:xlink="http://www.w3.org/1999/xlink">6 (30)</td>
###xml 922 927 922 927 <td xmlns:xlink="http://www.w3.org/1999/xlink">1 (4)</td>
###xml 927 933 927 933 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 (12)</td>
###xml 896 933 896 933 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;51&#8211;75%</td><td>9 (18)</td><td>10 (14)</td><td>6 (30)</td><td>1 (4)</td><td>3 (12)</td></tr>
###xml 933 941 933 941 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;76&#8211;100%</td>
###xml 941 948 941 948 <td xmlns:xlink="http://www.w3.org/1999/xlink">20 (40)</td>
###xml 948 955 948 955 <td xmlns:xlink="http://www.w3.org/1999/xlink">15 (22)</td>
###xml 955 962 955 962 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 (50)</td>
###xml 969 970 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 962 970 962 970 <td xmlns:xlink="http://www.w3.org/1999/xlink">22 (84)<sup>#</sup></td>
###xml 977 978 977 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 970 978 970 978 <td xmlns:xlink="http://www.w3.org/1999/xlink">17 (65)<sup>#</sup></td>
###xml 933 978 933 978 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;76&#8211;100%</td><td>20 (40)</td><td>15 (22)</td><td>10 (50)</td><td>22 (84)<sup>#</sup></td><td>17 (65)<sup>#</sup></td></tr>
###xml 978 995 978 993 <td xmlns:xlink="http://www.w3.org/1999/xlink">AI (mean &#177; SEM)</td>
###xml 995 1007 993 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.1&#8201;&#177;&#8201;0.22</td>
###xml 1007 1019 1003 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.4&#8201;&#177;&#8201;0.05</td>
###xml 1031 1045 1023 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#182;</sup>
###xml 1019 1045 1013 1024 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.5&#8201;&#177;&#8201;0.38<sup>&#182;</sup></td>
###xml 1045 1058 1024 1035 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0&#8201;&#177;&#8201;0.19*</td>
###xml 1058 1071 1035 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.1&#8201;&#177;&#8201;0.28*</td>
###xml 978 1071 978 1046 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>AI (mean &#177; SEM)</td><td>1.1&#8201;&#177;&#8201;0.22</td><td>0.4&#8201;&#177;&#8201;0.05</td><td>1.5&#8201;&#177;&#8201;0.38<sup>&#182;</sup></td><td>1.0&#8201;&#177;&#8201;0.19*</td><td>1.1&#8201;&#177;&#8201;0.28*</td></tr>
###xml 1071 1090 1046 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink">TILs (mean &#177; SEM)</td>
###xml 1090 1102 1063 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;0.96</td>
###xml 1114 1116 1083 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 1102 1116 1073 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.9&#8201;&#177;&#8201;0.38<sup>##</sup></td>
###xml 1129 1157 1096 1098 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#182;&#182;</sup>
###xml 1116 1157 1085 1098 <td xmlns:xlink="http://www.w3.org/1999/xlink">18.6&#8201;&#177;&#8201;4.84<sup>&#182;&#182;</sup></td>
###xml 1157 1169 1098 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.6&#8201;&#177;&#8201;1.27</td>
###xml 1169 1184 1108 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink">23.9&#8201;&#177;&#8201;6.60**</td>
###xml 1071 1184 1046 1121 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>TILs (mean &#177; SEM)</td><td>6.6&#8201;&#177;&#8201;0.96</td><td>3.9&#8201;&#177;&#8201;0.38<sup>##</sup></td><td>18.6&#8201;&#177;&#8201;4.84<sup>&#182;&#182;</sup></td><td>6.6&#8201;&#177;&#8201;1.27</td><td>23.9&#8201;&#177;&#8201;6.60**</td></tr>
###xml 775 1184 775 1121 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>&#160;n FasL + (%)</td><td>47 (94)</td><td>64 (93)</td><td>20 (100)</td><td>26 (100)</td><td>26 (100)</td></tr><tr><td>&#160;0&#8211;25%</td><td>17 (34)</td><td>35 (51)</td><td>3 (15)</td><td>2 (8)</td><td>4 (15)</td></tr><tr><td>&#160;26&#8211;50%</td><td>4 (8)</td><td>9 (13)</td><td>1 (5)</td><td>1 (4)</td><td>2 (8)</td></tr><tr><td>&#160;51&#8211;75%</td><td>9 (18)</td><td>10 (14)</td><td>6 (30)</td><td>1 (4)</td><td>3 (12)</td></tr><tr><td>&#160;76&#8211;100%</td><td>20 (40)</td><td>15 (22)</td><td>10 (50)</td><td>22 (84)<sup>#</sup></td><td>17 (65)<sup>#</sup></td></tr><tr><td>AI (mean &#177; SEM)</td><td>1.1&#8201;&#177;&#8201;0.22</td><td>0.4&#8201;&#177;&#8201;0.05</td><td>1.5&#8201;&#177;&#8201;0.38<sup>&#182;</sup></td><td>1.0&#8201;&#177;&#8201;0.19*</td><td>1.1&#8201;&#177;&#8201;0.28*</td></tr><tr><td>TILs (mean &#177; SEM)</td><td>6.6&#8201;&#177;&#8201;0.96</td><td>3.9&#8201;&#177;&#8201;0.38<sup>##</sup></td><td>18.6&#8201;&#177;&#8201;4.84<sup>&#182;&#182;</sup></td><td>6.6&#8201;&#177;&#8201;1.27</td><td>23.9&#8201;&#177;&#8201;6.60**</td></tr></tbody>
###xml 707 1184 707 1121 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="3">Carcinomas</th></tr><tr><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr><tr><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr></thead><tbody><tr><td>&#160;n FasL + (%)</td><td>47 (94)</td><td>64 (93)</td><td>20 (100)</td><td>26 (100)</td><td>26 (100)</td></tr><tr><td>&#160;0&#8211;25%</td><td>17 (34)</td><td>35 (51)</td><td>3 (15)</td><td>2 (8)</td><td>4 (15)</td></tr><tr><td>&#160;26&#8211;50%</td><td>4 (8)</td><td>9 (13)</td><td>1 (5)</td><td>1 (4)</td><td>2 (8)</td></tr><tr><td>&#160;51&#8211;75%</td><td>9 (18)</td><td>10 (14)</td><td>6 (30)</td><td>1 (4)</td><td>3 (12)</td></tr><tr><td>&#160;76&#8211;100%</td><td>20 (40)</td><td>15 (22)</td><td>10 (50)</td><td>22 (84)<sup>#</sup></td><td>17 (65)<sup>#</sup></td></tr><tr><td>AI (mean &#177; SEM)</td><td>1.1&#8201;&#177;&#8201;0.22</td><td>0.4&#8201;&#177;&#8201;0.05</td><td>1.5&#8201;&#177;&#8201;0.38<sup>&#182;</sup></td><td>1.0&#8201;&#177;&#8201;0.19*</td><td>1.1&#8201;&#177;&#8201;0.28*</td></tr><tr><td>TILs (mean &#177; SEM)</td><td>6.6&#8201;&#177;&#8201;0.96</td><td>3.9&#8201;&#177;&#8201;0.38<sup>##</sup></td><td>18.6&#8201;&#177;&#8201;4.84<sup>&#182;&#182;</sup></td><td>6.6&#8201;&#177;&#8201;1.27</td><td>23.9&#8201;&#177;&#8201;6.60**</td></tr></tbody></table>
###xml 1184 1185 1121 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1185 1186 1122 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1241 1255 1178 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#182;</sup>
###xml 1255 1256 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1300 1301 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1356 1358 1280 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 1358 1359 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1405 1433 1329 1331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#182;&#182;</sup>
###xml 1433 1434 1331 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1539 1540 1437 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1184 1594 1121 1492 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><sup>#</sup><italic>P</italic>&#8201;&lt;&#8201;0.001 for sporadic carcinomas vs sporadic adenomas; <sup>&#182;</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 for LS carcinomas vs LS adenomas; * <italic>p</italic>&#8201;&lt;&#8201;0.001 for sporadic carcinomas vs sporadic adenomas; <sup>##</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 for LS adenomas vs sporadic adenomas; <sup>&#182;&#182;</sup><italic>p</italic>&#8201;=&#8201;0.01 for LS carcinomas versus sporadic MSS carcinomas and &lt;0.001 for LS carcinomas vs LS adenomas; ** <italic>p</italic>&#8201;=&#8201;0.02 for sporadic MSI-H vs sporadic MSS carcinomas.</p>
###xml 1184 1594 1121 1492 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25"><sup>#</sup><italic>P</italic>&#8201;&lt;&#8201;0.001 for sporadic carcinomas vs sporadic adenomas; <sup>&#182;</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 for LS carcinomas vs LS adenomas; * <italic>p</italic>&#8201;&lt;&#8201;0.001 for sporadic carcinomas vs sporadic adenomas; <sup>##</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 for LS adenomas vs sporadic adenomas; <sup>&#182;&#182;</sup><italic>p</italic>&#8201;=&#8201;0.01 for LS carcinomas versus sporadic MSS carcinomas and &lt;0.001 for LS carcinomas vs LS adenomas; ** <italic>p</italic>&#8201;=&#8201;0.02 for sporadic MSI-H vs sporadic MSS carcinomas.</p></table-wrap-foot>
###xml 566 1594 566 1492 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="24">FasL expression, epithelial apoptosis (expressed as apoptotic index AI) and TILs in LS and sporadic colorectal adenomas and carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Adenomas</th><th colspan="3">Carcinomas</th></tr><tr><th>LS</th><th>Sporadic</th><th>LS</th><th>Sporadic MSS</th><th>Sporadic MSI-H</th></tr><tr><th>n</th><th>50</th><th>69</th><th>20</th><th>26</th><th>26</th></tr></thead><tbody><tr><td>&#160;n FasL + (%)</td><td>47 (94)</td><td>64 (93)</td><td>20 (100)</td><td>26 (100)</td><td>26 (100)</td></tr><tr><td>&#160;0&#8211;25%</td><td>17 (34)</td><td>35 (51)</td><td>3 (15)</td><td>2 (8)</td><td>4 (15)</td></tr><tr><td>&#160;26&#8211;50%</td><td>4 (8)</td><td>9 (13)</td><td>1 (5)</td><td>1 (4)</td><td>2 (8)</td></tr><tr><td>&#160;51&#8211;75%</td><td>9 (18)</td><td>10 (14)</td><td>6 (30)</td><td>1 (4)</td><td>3 (12)</td></tr><tr><td>&#160;76&#8211;100%</td><td>20 (40)</td><td>15 (22)</td><td>10 (50)</td><td>22 (84)<sup>#</sup></td><td>17 (65)<sup>#</sup></td></tr><tr><td>AI (mean &#177; SEM)</td><td>1.1&#8201;&#177;&#8201;0.22</td><td>0.4&#8201;&#177;&#8201;0.05</td><td>1.5&#8201;&#177;&#8201;0.38<sup>&#182;</sup></td><td>1.0&#8201;&#177;&#8201;0.19*</td><td>1.1&#8201;&#177;&#8201;0.28*</td></tr><tr><td>TILs (mean &#177; SEM)</td><td>6.6&#8201;&#177;&#8201;0.96</td><td>3.9&#8201;&#177;&#8201;0.38<sup>##</sup></td><td>18.6&#8201;&#177;&#8201;4.84<sup>&#182;&#182;</sup></td><td>6.6&#8201;&#177;&#8201;1.27</td><td>23.9&#8201;&#177;&#8201;6.60**</td></tr></tbody></table><table-wrap-foot><p textid="25"><sup>#</sup><italic>P</italic>&#8201;&lt;&#8201;0.001 for sporadic carcinomas vs sporadic adenomas; <sup>&#182;</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 for LS carcinomas vs LS adenomas; * <italic>p</italic>&#8201;&lt;&#8201;0.001 for sporadic carcinomas vs sporadic adenomas; <sup>##</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 for LS adenomas vs sporadic adenomas; <sup>&#182;&#182;</sup><italic>p</italic>&#8201;=&#8201;0.01 for LS carcinomas versus sporadic MSS carcinomas and &lt;0.001 for LS carcinomas vs LS adenomas; ** <italic>p</italic>&#8201;=&#8201;0.02 for sporadic MSI-H vs sporadic MSS carcinomas.</p></table-wrap-foot></table-wrap>
Staining results are summarized in Table 2. FasL expression in epithelial cells was seen in 47/50 LS-associated adenomas and 64/69 sporadic adenomas (not significantly different). FasL expression was cytoplasmic and generally heterogeneously distributed within adenomatous tissue. In both groups, approximately half of the samples displayed expression in more than 50% of tumour cells. The extent of FasL positivity was not related to age, gender, adenoma size, location, degree of dysplasia or villous architecture, neither in LS-associated, nor in sporadic cases. Table 2FasL expression, epithelial apoptosis (expressed as apoptotic index AI) and TILs in LS and sporadic colorectal adenomas and carcinomas AdenomasCarcinomasLSSporadicLSSporadic MSSSporadic MSI-Hn5069202626 n FasL + (%)47 (94)64 (93)20 (100)26 (100)26 (100) 0-25%17 (34)35 (51)3 (15)2 (8)4 (15) 26-50%4 (8)9 (13)1 (5)1 (4)2 (8) 51-75%9 (18)10 (14)6 (30)1 (4)3 (12) 76-100%20 (40)15 (22)10 (50)22 (84)#17 (65)#AI (mean +/- SEM)1.1 +/- 0.220.4 +/- 0.051.5 +/- 0.38paragraph sign1.0 +/- 0.19*1.1 +/- 0.28*TILs (mean +/- SEM)6.6 +/- 0.963.9 +/- 0.38##18.6 +/- 4.84paragraph signparagraph sign6.6 +/- 1.2723.9 +/- 6.60**#P < 0.001 for sporadic carcinomas vs sporadic adenomas; paragraph signp < 0.05 for LS carcinomas vs LS adenomas; * p < 0.001 for sporadic carcinomas vs sporadic adenomas; ##p < 0.05 for LS adenomas vs sporadic adenomas; paragraph signparagraph signp = 0.01 for LS carcinomas versus sporadic MSS carcinomas and <0.001 for LS carcinomas vs LS adenomas; ** p = 0.02 for sporadic MSI-H vs sporadic MSS carcinomas.
###end p 23
###begin p 24
FasL expression, epithelial apoptosis (expressed as apoptotic index AI) and TILs in LS and sporadic colorectal adenomas and carcinomas
###end p 24
###begin p 25
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 57 71 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#182;</sup>
###xml 71 72 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 116 117 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 172 174 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 174 175 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 221 249 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#182;&#182;</sup>
###xml 249 250 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 355 356 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
#P < 0.001 for sporadic carcinomas vs sporadic adenomas; paragraph signp < 0.05 for LS carcinomas vs LS adenomas; * p < 0.001 for sporadic carcinomas vs sporadic adenomas; ##p < 0.05 for LS adenomas vs sporadic adenomas; paragraph signparagraph signp = 0.01 for LS carcinomas versus sporadic MSS carcinomas and <0.001 for LS carcinomas vs LS adenomas; ** p = 0.02 for sporadic MSI-H vs sporadic MSS carcinomas.
###end p 25
###begin p 26
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 637 638 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 715 721 715 721 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 721 975 721 975 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">FasL expression (brown) in colorectal carcinomas with adjacent normal mucosa. A, Cancer associated with Lynch syndrome; B, Sporadic cancer. In both cases, stronger expression of FasL in tumour cells was seen compared to normal cells (magnification &#215; 100)</p>
###xml 721 975 721 975 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">FasL expression (brown) in colorectal carcinomas with adjacent normal mucosa. A, Cancer associated with Lynch syndrome; B, Sporadic cancer. In both cases, stronger expression of FasL in tumour cells was seen compared to normal cells (magnification &#215; 100)</p></caption>
###xml 975 975 975 975 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12253_2008_9136_Fig1_HTML" id="MO1"/>
###xml 715 975 715 975 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="27">FasL expression (brown) in colorectal carcinomas with adjacent normal mucosa. A, Cancer associated with Lynch syndrome; B, Sporadic cancer. In both cases, stronger expression of FasL in tumour cells was seen compared to normal cells (magnification &#215; 100)</p></caption><graphic position="anchor" xlink:href="12253_2008_9136_Fig1_HTML" id="MO1"/></fig>
In carcinomas, FasL expression was present in all samples investigated. FasL expression was generally heterogeneously distributed. Percentages of positively staining cells were similar in LS, MSS and MSI-H sporadic tumours. In all three groups, approximately 80% of cases demonstrated FasL expression in more than 50% of cells. FasL expression was not related to age, gender, tumour location or degree of differentiation. When comparing FasL expression in adenomas and carcinomas, it was similar in LS-associated neoplasms (Fig. 1). In sporadic cases, percentages of positively staining cells were higher in carcinomas than in adenomas (p < 0.001). This was true for MSS carcinomas as well as for MSI-H carcinomas. Fig. 1FasL expression (brown) in colorectal carcinomas with adjacent normal mucosa. A, Cancer associated with Lynch syndrome; B, Sporadic cancer. In both cases, stronger expression of FasL in tumour cells was seen compared to normal cells (magnification x 100)
###end p 26
###begin p 27
FasL expression (brown) in colorectal carcinomas with adjacent normal mucosa. A, Cancer associated with Lynch syndrome; B, Sporadic cancer. In both cases, stronger expression of FasL in tumour cells was seen compared to normal cells (magnification x 100)
###end p 27
###begin title 28
Tumour Cell Apoptosis and Number of TILs in LS and Sporadic Colorectal Neoplasms
###end title 28
###begin p 29
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 334 335 334 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 493 499 493 499 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 499 621 499 621 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Example of M30 immunoreactivity in colon cancer, showing three cells with brown cytoplasmic staining (magnification &#215; 100)</p>
###xml 499 621 499 621 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Example of M30 immunoreactivity in colon cancer, showing three cells with brown cytoplasmic staining (magnification &#215; 100)</p></caption>
###xml 621 621 621 621 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12253_2008_9136_Fig2_HTML" id="MO2"/>
###xml 493 621 493 621 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="30">Example of M30 immunoreactivity in colon cancer, showing three cells with brown cytoplasmic staining (magnification &#215; 100)</p></caption><graphic position="anchor" xlink:href="12253_2008_9136_Fig2_HTML" id="MO2"/></fig>
The level of tumour cell apoptosis, assessed by M30 immunoreactivity (Fig. 2), was similar between LS and sporadic adenomas, although there was a non-significant trend towards higher levels in LS adenomas (p = 0.08). The same trend was observed in LS carcinomas, with apoptotic indices being slightly higher than in sporadic cancers (p = 0.07). When comparing carcinomas with adenomas, mean apoptotic indices were higher in carcinomas, both in LS (p < 0.05) and in sporadic cases (p < 0.001). Fig. 2Example of M30 immunoreactivity in colon cancer, showing three cells with brown cytoplasmic staining (magnification x 100)
###end p 29
###begin p 30
Example of M30 immunoreactivity in colon cancer, showing three cells with brown cytoplasmic staining (magnification x 100)
###end p 30
###begin p 31
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 306 307 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 463 464 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 718 724 710 716 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 724 1044 716 1036 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Staining of tumour-infiltrating lymphocytes (TILs) by CD8 immunoreactivity (brown). A, Lynch syndrome associated cancer; B, Sporadic MSS cancer; C, Lynch syndrome associated adenoma; D, Sporadic adenoma. The number of TILs is higher in cases associated with Lynch syndrome compared to sporadic ones (magnification &#215; 400)</p>
###xml 724 1044 716 1036 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Staining of tumour-infiltrating lymphocytes (TILs) by CD8 immunoreactivity (brown). A, Lynch syndrome associated cancer; B, Sporadic MSS cancer; C, Lynch syndrome associated adenoma; D, Sporadic adenoma. The number of TILs is higher in cases associated with Lynch syndrome compared to sporadic ones (magnification &#215; 400)</p></caption>
###xml 1044 1044 1036 1036 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12253_2008_9136_Fig3_HTML" id="MO3"/>
###xml 718 1044 710 1036 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="32">Staining of tumour-infiltrating lymphocytes (TILs) by CD8 immunoreactivity (brown). A, Lynch syndrome associated cancer; B, Sporadic MSS cancer; C, Lynch syndrome associated adenoma; D, Sporadic adenoma. The number of TILs is higher in cases associated with Lynch syndrome compared to sporadic ones (magnification &#215; 400)</p></caption><graphic position="anchor" xlink:href="12253_2008_9136_Fig3_HTML" id="MO3"/></fig>
The number of TILs, assessed by CD8 positivity, was higher in LS adenomas compared with sporadic adenomas (p < 0.05, Fig. 3). Within the group of LS adenomas, the mean number of TILs was higher in adenomas with high-grade dysplasia compared with those with low-grade dysplasia (8.8 +/- 1.8 vs 4.7 +/- 0.8, p < 0.001). The mean number of TILs was also higher in adenomas with proximal location compared with those with distal location (9.4 +/- 1.9 vs 4.7 +/- 0.8, p < 0.001). The mean number of TILs was not correlated with adenoma size or the presence of villous architecture in LS adenomas. In sporadic adenomas, the number of TILs was not correlated with adenoma size, degree of dysplasia, architecture or location. Fig. 3Staining of tumour-infiltrating lymphocytes (TILs) by CD8 immunoreactivity (brown). A, Lynch syndrome associated cancer; B, Sporadic MSS cancer; C, Lynch syndrome associated adenoma; D, Sporadic adenoma. The number of TILs is higher in cases associated with Lynch syndrome compared to sporadic ones (magnification x 400)
###end p 31
###begin p 32
Staining of tumour-infiltrating lymphocytes (TILs) by CD8 immunoreactivity (brown). A, Lynch syndrome associated cancer; B, Sporadic MSS cancer; C, Lynch syndrome associated adenoma; D, Sporadic adenoma. The number of TILs is higher in cases associated with Lynch syndrome compared to sporadic ones (magnification x 400)
###end p 32
###begin p 33
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
In carcinomas, the number of TILs was similar in LS-associated carcinomas and MSI-H sporadic cancers but higher in both these groups than in MSS sporadic tumours (p = 0.01 and 0.02 respectively, Fig. 3). In LS-associated tumours, TIL density was higher in carcinomas than in adenomas (p < 0.001). There was no correlation between the number of TILs and tumour location or degree of differentiation. This was the case in LS-associated cancers as well as in sporadic cancers.
###end p 33
###begin title 34
Relationship Between FasL Expression, Tumour Cell Apoptosis and TILs
###end title 34
###begin p 35
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1007 1014 1007 1014 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1014 1184 1014 1180 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Relationship between FasL expression, epithelial apoptosis (expressed as apoptotic index AI, mean &#177; SEM) and TILs (mean &#177; SEM) in LS and sporadic colorectal neoplasms</p>
###xml 1014 1184 1014 1180 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Relationship between FasL expression, epithelial apoptosis (expressed as apoptotic index AI, mean &#177; SEM) and TILs (mean &#177; SEM) in LS and sporadic colorectal neoplasms</p></caption>
###xml 1184 1185 1180 1181 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 1185 1211 1181 1207 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">LS adenomas and carcinomas</th>
###xml 1211 1247 1207 1243 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Sporadic adenomas and MSS carcinomas</th>
###xml 1184 1247 1180 1243 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="3">LS adenomas and carcinomas</th><th colspan="3">Sporadic adenomas and MSS carcinomas</th></tr>
###xml 1247 1248 1243 1244 <th xmlns:xlink="http://www.w3.org/1999/xlink">n</th>
###xml 1248 1250 1244 1246 <th xmlns:xlink="http://www.w3.org/1999/xlink">AI</th>
###xml 1250 1254 1246 1250 <th xmlns:xlink="http://www.w3.org/1999/xlink">TILs</th>
###xml 1254 1255 1250 1251 <th xmlns:xlink="http://www.w3.org/1999/xlink">n</th>
###xml 1255 1257 1251 1253 <th xmlns:xlink="http://www.w3.org/1999/xlink">AI</th>
###xml 1257 1261 1253 1257 <th xmlns:xlink="http://www.w3.org/1999/xlink">TILs</th>
###xml 1247 1261 1243 1257 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>n</th><th>AI</th><th>TILs</th><th>n</th><th>AI</th><th>TILs</th></tr>
###xml 1184 1261 1180 1257 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="3">LS adenomas and carcinomas</th><th colspan="3">Sporadic adenomas and MSS carcinomas</th></tr><tr><th>n</th><th>AI</th><th>TILs</th><th>n</th><th>AI</th><th>TILs</th></tr></thead>
###xml 1261 1276 1257 1272 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="7">FasL expression</td>
###xml 1261 1276 1257 1272 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="7">FasL expression</td></tr>
###xml 1276 1281 1272 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;25%</td>
###xml 1281 1283 1277 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink">20</td>
###xml 1283 1296 1279 1290 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.99&#8201;&#177;&#8201;0.25</td>
###xml 1296 1307 1290 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.7&#8201;&#177;&#8201;1.5</td>
###xml 1307 1309 1299 1301 <td xmlns:xlink="http://www.w3.org/1999/xlink">39</td>
###xml 1309 1322 1301 1312 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.43&#8201;&#177;&#8201;0.07</td>
###xml 1322 1333 1312 1321 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.4&#8201;&#177;&#8201;0.4</td>
###xml 1276 1333 1272 1321 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>0&#8211;25%</td><td>20</td><td>0.99&#8201;&#177;&#8201;0.25</td><td>6.7&#8201;&#177;&#8201;1.5</td><td>39</td><td>0.43&#8201;&#177;&#8201;0.07</td><td>3.4&#8201;&#177;&#8201;0.4</td></tr>
###xml 1333 1339 1321 1327 <td xmlns:xlink="http://www.w3.org/1999/xlink">26&#8211;50%</td>
###xml 1339 1340 1327 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 1340 1353 1328 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.84&#8201;&#177;&#8201;1.28</td>
###xml 1353 1365 1339 1349 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.7&#8201;&#177;&#8201;4.7</td>
###xml 1365 1367 1349 1351 <td xmlns:xlink="http://www.w3.org/1999/xlink">11</td>
###xml 1367 1380 1351 1362 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.68&#8201;&#177;&#8201;0.19</td>
###xml 1380 1391 1362 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.3&#8201;&#177;&#8201;1.9</td>
###xml 1333 1391 1321 1371 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>26&#8211;50%</td><td>5</td><td>1.84&#8201;&#177;&#8201;1.28</td><td>10.7&#8201;&#177;&#8201;4.7</td><td>11</td><td>0.68&#8201;&#177;&#8201;0.19</td><td>5.3&#8201;&#177;&#8201;1.9</td></tr>
###xml 1391 1397 1371 1377 <td xmlns:xlink="http://www.w3.org/1999/xlink">51&#8211;75%</td>
###xml 1397 1399 1377 1379 <td xmlns:xlink="http://www.w3.org/1999/xlink">17</td>
###xml 1399 1412 1379 1390 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.45&#8201;&#177;&#8201;0.48</td>
###xml 1412 1424 1390 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.9&#8201;&#177;&#8201;4.8</td>
###xml 1424 1426 1400 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink">13</td>
###xml 1426 1439 1402 1413 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.47&#8201;&#177;&#8201;0.09</td>
###xml 1439 1450 1413 1422 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.9&#8201;&#177;&#8201;0.8</td>
###xml 1391 1450 1371 1422 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>51&#8211;75%</td><td>17</td><td>1.45&#8201;&#177;&#8201;0.48</td><td>11.9&#8201;&#177;&#8201;4.8</td><td>13</td><td>0.47&#8201;&#177;&#8201;0.09</td><td>3.9&#8201;&#177;&#8201;0.8</td></tr>
###xml 1450 1457 1422 1429 <td xmlns:xlink="http://www.w3.org/1999/xlink">76&#8211;100%</td>
###xml 1457 1459 1429 1431 <td xmlns:xlink="http://www.w3.org/1999/xlink">28</td>
###xml 1459 1472 1431 1442 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.13&#8201;&#177;&#8201;0.27</td>
###xml 1472 1484 1442 1452 <td xmlns:xlink="http://www.w3.org/1999/xlink">11.1&#8201;&#177;&#8201;2.7</td>
###xml 1484 1486 1452 1454 <td xmlns:xlink="http://www.w3.org/1999/xlink">32</td>
###xml 1486 1499 1454 1465 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.82&#8201;&#177;&#8201;0.15</td>
###xml 1499 1510 1465 1474 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.3&#8201;&#177;&#8201;1.0</td>
###xml 1450 1510 1422 1474 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>76&#8211;100%</td><td>28</td><td>1.13&#8201;&#177;&#8201;0.27</td><td>11.1&#8201;&#177;&#8201;2.7</td><td>32</td><td>0.82&#8201;&#177;&#8201;0.15</td><td>6.3&#8201;&#177;&#8201;1.0</td></tr>
###xml 1510 1515 1474 1479 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total</td>
###xml 1515 1517 1479 1481 <td xmlns:xlink="http://www.w3.org/1999/xlink">70</td>
###xml 1517 1530 1481 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.22&#8201;&#177;&#8201;0.19</td>
###xml 1530 1543 1492 1503 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.0&#8201;&#177;&#8201;1.65</td>
###xml 1543 1545 1503 1505 <td xmlns:xlink="http://www.w3.org/1999/xlink">95</td>
###xml 1545 1558 1505 1516 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.59&#8201;&#177;&#8201;0.07</td>
###xml 1558 1569 1516 1525 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.7&#8201;&#177;&#8201;0.5</td>
###xml 1510 1569 1474 1525 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total</td><td>70</td><td>1.22&#8201;&#177;&#8201;0.19</td><td>10.0&#8201;&#177;&#8201;1.65</td><td>95</td><td>0.59&#8201;&#177;&#8201;0.07</td><td>4.7&#8201;&#177;&#8201;0.5</td></tr>
###xml 1261 1569 1257 1525 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="7">FasL expression</td></tr><tr><td>0&#8211;25%</td><td>20</td><td>0.99&#8201;&#177;&#8201;0.25</td><td>6.7&#8201;&#177;&#8201;1.5</td><td>39</td><td>0.43&#8201;&#177;&#8201;0.07</td><td>3.4&#8201;&#177;&#8201;0.4</td></tr><tr><td>26&#8211;50%</td><td>5</td><td>1.84&#8201;&#177;&#8201;1.28</td><td>10.7&#8201;&#177;&#8201;4.7</td><td>11</td><td>0.68&#8201;&#177;&#8201;0.19</td><td>5.3&#8201;&#177;&#8201;1.9</td></tr><tr><td>51&#8211;75%</td><td>17</td><td>1.45&#8201;&#177;&#8201;0.48</td><td>11.9&#8201;&#177;&#8201;4.8</td><td>13</td><td>0.47&#8201;&#177;&#8201;0.09</td><td>3.9&#8201;&#177;&#8201;0.8</td></tr><tr><td>76&#8211;100%</td><td>28</td><td>1.13&#8201;&#177;&#8201;0.27</td><td>11.1&#8201;&#177;&#8201;2.7</td><td>32</td><td>0.82&#8201;&#177;&#8201;0.15</td><td>6.3&#8201;&#177;&#8201;1.0</td></tr><tr><td>Total</td><td>70</td><td>1.22&#8201;&#177;&#8201;0.19</td><td>10.0&#8201;&#177;&#8201;1.65</td><td>95</td><td>0.59&#8201;&#177;&#8201;0.07</td><td>4.7&#8201;&#177;&#8201;0.5</td></tr></tbody>
###xml 1184 1569 1180 1525 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">LS adenomas and carcinomas</th><th colspan="3">Sporadic adenomas and MSS carcinomas</th></tr><tr><th>n</th><th>AI</th><th>TILs</th><th>n</th><th>AI</th><th>TILs</th></tr></thead><tbody><tr><td colspan="7">FasL expression</td></tr><tr><td>0&#8211;25%</td><td>20</td><td>0.99&#8201;&#177;&#8201;0.25</td><td>6.7&#8201;&#177;&#8201;1.5</td><td>39</td><td>0.43&#8201;&#177;&#8201;0.07</td><td>3.4&#8201;&#177;&#8201;0.4</td></tr><tr><td>26&#8211;50%</td><td>5</td><td>1.84&#8201;&#177;&#8201;1.28</td><td>10.7&#8201;&#177;&#8201;4.7</td><td>11</td><td>0.68&#8201;&#177;&#8201;0.19</td><td>5.3&#8201;&#177;&#8201;1.9</td></tr><tr><td>51&#8211;75%</td><td>17</td><td>1.45&#8201;&#177;&#8201;0.48</td><td>11.9&#8201;&#177;&#8201;4.8</td><td>13</td><td>0.47&#8201;&#177;&#8201;0.09</td><td>3.9&#8201;&#177;&#8201;0.8</td></tr><tr><td>76&#8211;100%</td><td>28</td><td>1.13&#8201;&#177;&#8201;0.27</td><td>11.1&#8201;&#177;&#8201;2.7</td><td>32</td><td>0.82&#8201;&#177;&#8201;0.15</td><td>6.3&#8201;&#177;&#8201;1.0</td></tr><tr><td>Total</td><td>70</td><td>1.22&#8201;&#177;&#8201;0.19</td><td>10.0&#8201;&#177;&#8201;1.65</td><td>95</td><td>0.59&#8201;&#177;&#8201;0.07</td><td>4.7&#8201;&#177;&#8201;0.5</td></tr></tbody></table>
###xml 1007 1569 1007 1525 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="36">Relationship between FasL expression, epithelial apoptosis (expressed as apoptotic index AI, mean &#177; SEM) and TILs (mean &#177; SEM) in LS and sporadic colorectal neoplasms</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="3">LS adenomas and carcinomas</th><th colspan="3">Sporadic adenomas and MSS carcinomas</th></tr><tr><th>n</th><th>AI</th><th>TILs</th><th>n</th><th>AI</th><th>TILs</th></tr></thead><tbody><tr><td colspan="7">FasL expression</td></tr><tr><td>0&#8211;25%</td><td>20</td><td>0.99&#8201;&#177;&#8201;0.25</td><td>6.7&#8201;&#177;&#8201;1.5</td><td>39</td><td>0.43&#8201;&#177;&#8201;0.07</td><td>3.4&#8201;&#177;&#8201;0.4</td></tr><tr><td>26&#8211;50%</td><td>5</td><td>1.84&#8201;&#177;&#8201;1.28</td><td>10.7&#8201;&#177;&#8201;4.7</td><td>11</td><td>0.68&#8201;&#177;&#8201;0.19</td><td>5.3&#8201;&#177;&#8201;1.9</td></tr><tr><td>51&#8211;75%</td><td>17</td><td>1.45&#8201;&#177;&#8201;0.48</td><td>11.9&#8201;&#177;&#8201;4.8</td><td>13</td><td>0.47&#8201;&#177;&#8201;0.09</td><td>3.9&#8201;&#177;&#8201;0.8</td></tr><tr><td>76&#8211;100%</td><td>28</td><td>1.13&#8201;&#177;&#8201;0.27</td><td>11.1&#8201;&#177;&#8201;2.7</td><td>32</td><td>0.82&#8201;&#177;&#8201;0.15</td><td>6.3&#8201;&#177;&#8201;1.0</td></tr><tr><td>Total</td><td>70</td><td>1.22&#8201;&#177;&#8201;0.19</td><td>10.0&#8201;&#177;&#8201;1.65</td><td>95</td><td>0.59&#8201;&#177;&#8201;0.07</td><td>4.7&#8201;&#177;&#8201;0.5</td></tr></tbody></table></table-wrap>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
To search support for the FasL counterattack hypothesis, we determined whether higher FasL expression in neoplasms was associated with lower levels of tumour cell apoptosis or reduced TIL densities (Table 3). For this analysis, adenomas and carcinomas from LS patients and were taken together as well as adenomas and MSS carcinomas from sporadic origin. In LS-associated cases, there were no positive or negative correlations between the percentage of FasL positivity on the one hand and levels of tumour cell apoptosis or number of TILs on the other. There was also no correlation between the degree of tumour cell apoptosis and the number of TILs. In contrast, in sporadic cases, there was a positive correlation between higher FasL expression and degree of tumour cell apoptosis (Spearman's rho correlation coefficient 0.27, p = 0.008). There was no correlation between FasL expression and the number of TILs, nor between the degree of tumour cell apoptosis and the number of TILs in sporadic neoplasms. Table 3Relationship between FasL expression, epithelial apoptosis (expressed as apoptotic index AI, mean +/- SEM) and TILs (mean +/- SEM) in LS and sporadic colorectal neoplasms LS adenomas and carcinomasSporadic adenomas and MSS carcinomasnAITILsnAITILsFasL expression0-25%200.99 +/- 0.256.7 +/- 1.5390.43 +/- 0.073.4 +/- 0.426-50%51.84 +/- 1.2810.7 +/- 4.7110.68 +/- 0.195.3 +/- 1.951-75%171.45 +/- 0.4811.9 +/- 4.8130.47 +/- 0.093.9 +/- 0.876-100%281.13 +/- 0.2711.1 +/- 2.7320.82 +/- 0.156.3 +/- 1.0Total701.22 +/- 0.1910.0 +/- 1.65950.59 +/- 0.074.7 +/- 0.5
###end p 35
###begin p 36
Relationship between FasL expression, epithelial apoptosis (expressed as apoptotic index AI, mean +/- SEM) and TILs (mean +/- SEM) in LS and sporadic colorectal neoplasms
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 132 140 <span type="species:ncbi:9606">patients</span>
In this study, we sought to determine whether the Fas counterattack plays a role in the accelerated colorectal carcinogenesis in LS patients compared to sporadic disease. We found no support for such a mechanism, as FasL expression was similar between LS and sporadic tumours. In addition, there were no correlations between the percentages of FasL positivity and the number of TILs. A novel finding from our study was that LS-associated adenomas, in addition to LS-associated carcinomas, are also characterized by higher numbers of TILs compared to sporadic cases.
###end p 38
###begin p 39
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
Colorectal carcinogenesis in LS is believed to be accelerated when compared with sporadic cases. This is illustrated by the relative frequent occurrence of interval cancers between regular surveillance colonoscopies. In addition, LS-associated adenomas frequently harbour villous components and high-grade dysplasia, which both are markers of increased cancer risk. Differences between LS and sporadic colorectal neoplasms have been extensively studied, demonstrating differences in molecular genetic alterations [23-26] and histopathological characteristics [6, 15, 27, 28]. The accelerated carcinogenesis in LS does not seem to be reflected by a difference in degree of apoptosis with sporadic carcinogenesis [29, 30], although several differences in expression of apoptosis-regulating proteins have been found [30, 31, 32]. To our knowledge, FasL expression has not been studied before in LS-associated neoplasms. Our results indicate similar expression patterns of FasL in LS and sporadic neoplasms. So, FasL expression seems to occur early in colorectal carcinogenesis, irrespective of the sporadic or hereditary origin of the lesions.
###end p 39
###begin p 40
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
We found that FasL expression was more prevalent in carcinomas than in adenomas, consistent with other reports [10-13]. It was recently demonstrated that MSI-H tumours were associated with a reduced frequency of FasL expression relative to non-MSI-H tumours [33]. In our study, a similar trend was seen although this did not reach statistical significance.
###end p 40
###begin p 41
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 930 931 930 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1104 1106 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1108 1110 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 1094 1102 <span type="species:ncbi:9606">patients</span>
Infiltration of lymphocytes is a prominent feature of MSI-H tumours, including LS-associated colorectal cancer [21, 22, 27, 34]. This was confirmed in the present report. In this study, we show for the first time that LS-associated adenomas display the same feature. Moreover, we found that the mean number of TILs was higher in LS adenomas with high-grade dysplasia compared with those with low-grade dysplasia. Only few studies are available that have evaluated the degree of infiltration with lymphocytes in adenomas [35-37]. From these studies, it appears that the number of TILs increases in the course of the adenoma-carcinoma sequence, which is corresponding to our results. It has also been shown that the number of TILs is an independent prognostic factor in colorectal cancer [38-40]. As LS-associated colorectal cancer and sporadic MSI-H colorectal cancer are associated with better survival rates than sporadic cases [1], it has been suggested that the presence of a cytotoxic anti-tumour immune response may at least in part contribute to the survival advantage described in these patients [34, 38]. Whether TILs in LS-associated and MSI-H sporadic tumours are really activated cytotoxic T-cells remains to be demonstrated.
###end p 41
###begin p 42
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 1021 1023 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 1117 1119 1117 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 1498 1499 1498 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1501 1503 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
The aim of our study was to determine whether higher FasL expression in neoplasms was associated with lower levels of tumour cell apoptosis or increased levels of apoptotic TILs, reflected by reduced TIL density. We found no such correlations in LS-associated neoplasms. In sporadic cases, a positive rather than a negative correlation between FasL expression and tumour cell apoptosis was found. This finding may be a consequence of elevated FasL levels triggering tumour cell apoptosis in a manner similar to autocrine suicide of activated T-cells [41]. Our findings are in contrast with those from Houston et al, who did not find a correlation between FasL expression and degree of tumour cell apoptosis [42]. It must be noted that their series consisted of only ten colorectal tumours, which may explain the absence of a correlation in their study. The same research group recently found a non-significant negative association between intensity of FasL staining and number of TILs in a series of 91 colon carcinomas [43]. Two studies reported a positive correlation between FasL expression and apoptosis in TILs [43, 44], whereas we did not find an association between FasL expression and TIL density. The background for the discrepancy between these data and ours is unclear. A possible explanation may lie in the fact that in the other studies TUNEL and ISNT were used to assess TIL apoptosis. Both these techniques have poor specificity for apoptosis and their use is currently discouraged [7, 45].
###end p 42
###begin p 43
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">50</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">51</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">52</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">53</xref>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 1245 1247 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 955 959 <span type="species:ncbi:10090">mice</span>
The question whether the Fas counterattack plays a role at all in colorectal carcinogenesis is surrounded with controversy [46, 47]. The idea behind the concept is that FasL expression by tumour cells may enable those cells to kill anti-tumour immune effector T-cells that infiltrate the tumour. Many tumours and tumour cell lines of varying histologic origin express FasL [48]. Several functional studies have shown that FasL positive colon tumour cells can induce apoptosis of Fas-sensitive lymphocytes in vitro [49, 50]. In addition, inhibition of FasL expression reduced tumour development and growth in a xenograft experiment [51]. There are however also experimental data which seriously question the concept of the Fas counterattack. In a replication study, FasL-expressing colon cancer cells did not induce apoptosis in Fas-sensitive target cells [52]. In a gene transfer experiment, Fas resistant colon cancer cells, subcutaneously injected into mice, rapidly regressed upon transfection with FasL [53]. In another experiment, cytotoxic T-cells were not sensitive to FasL displayed on the surface of antigen-presenting cells [54]. Taken together, the role of the Fas counterattack in colorectal carcinogenesis is at least questionable [48].
###end p 43
###begin p 44
In conclusion, we observed upregulation of FasL during colorectal carcinogenesis, both in LS-associated and in sporadic cases, without a correlation with the number of TILs. Our data do not support an important role for the Fas counterattack as a mechanism behind the difference between colorectal carcinogenesis in LS-associated and sporadic cases.
###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
This study was supported by the Dutch Cancer Society, grant RUG 1998-1660 and the Dutch Digestive Diseases Foundation, grant 2001-31.
###end p 46
###begin p 47
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 47
###begin title 48
References
###end title 48
###begin article-title 49
Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians
###end article-title 49
###begin article-title 50
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer
###end article-title 50
###begin article-title 51
Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families
###end article-title 51
###begin article-title 52
Interval cancers in hereditary nonpolyposis colorectal cancer (Lynch syndrome)
###end article-title 52
###begin article-title 53
Frequency and type of colorectal tumors in asymptomatic high-risk individuals in families with hereditary nonpolyposis colorectal cancer
###end article-title 53
###begin article-title 54
Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation
###end article-title 54
###begin article-title 55
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature
###end article-title 55
###begin article-title 56
Microsatellite instability in the development of DNA mismatch repair deficient tumors
###end article-title 56
###begin article-title 57
Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
###end article-title 57
###begin article-title 58
Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence
###end article-title 58
###begin article-title 59
Fas ligand upregulation is an early event in colonic carcinogenesis
###end article-title 59
###begin article-title 60
Expression of Fas ligand is an early event in colorectal carcinogenesis
###end article-title 60
###begin article-title 61
Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus
###end article-title 61
###begin article-title 62
###xml 138 143 <span type="species:ncbi:9606">human</span>
Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
###end article-title 62
###begin article-title 63
Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status
###end article-title 63
###begin article-title 64
###xml 146 154 <span type="species:ncbi:9606">patients</span>
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients
###end article-title 64
###begin article-title 65
Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas
###end article-title 65
###begin article-title 66
The World Health Organization's histologic classification of gastrointestinal tumors
###end article-title 66
###begin article-title 67
Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis
###end article-title 67
###begin article-title 68
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis
###end article-title 68
###begin article-title 69
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability
###end article-title 69
###begin article-title 70
Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma
###end article-title 70
###begin article-title 71
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
###end article-title 71
###begin article-title 72
Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome
###end article-title 72
###begin article-title 73
Biologic characterization of hereditary non-polyposis colorectal cancer
###end article-title 73
###begin article-title 74
Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas
###end article-title 74
###begin article-title 75
HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences
###end article-title 75
###begin article-title 76
Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis
###end article-title 76
###begin article-title 77
Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas
###end article-title 77
###begin article-title 78
Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers
###end article-title 78
###begin article-title 79
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers
###end article-title 79
###begin article-title 80
The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability
###end article-title 80
###begin article-title 81
Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status
###end article-title 81
###begin article-title 82
Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas
###end article-title 82
###begin article-title 83
Cytotoxic intraepithelial lymphocytes in colorectal polyps and carcinomas
###end article-title 83
###begin article-title 84
Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas
###end article-title 84
###begin article-title 85
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis
###end article-title 85
###begin article-title 86
###xml 76 81 <span type="species:ncbi:9606">human</span>
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer
###end article-title 86
###begin article-title 87
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer
###end article-title 87
###begin article-title 88
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
###end article-title 88
###begin article-title 89
Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo
###end article-title 89
###begin article-title 90
###xml 61 66 <span type="species:ncbi:9606">human</span>
Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression
###end article-title 90
###begin article-title 91
###xml 89 94 <span type="species:ncbi:9606">human</span>
Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis
###end article-title 91
###begin article-title 92
Viewing apoptosis through a TUNEL
###end article-title 92
###begin article-title 93
Immune privilege or inflammation? Insights into the Fas ligand enigma
###end article-title 93
###begin article-title 94
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
###end article-title 94
###begin article-title 95
CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts
###end article-title 95
###begin article-title 96
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape
###end article-title 96
###begin article-title 97
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
###end article-title 97
###begin article-title 98
Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo
###end article-title 98
###begin article-title 99
Gene transfer of Fas ligand induces tumor regression in vivo
###end article-title 99
###begin article-title 100
CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity
###end article-title 100
###begin title 101
Abbreviations
###end title 101
###begin p 102
Fas Ligand
###end p 102
###begin p 103
tumour-infiltrating lymphocytes
###end p 103
###begin p 104
Lynch syndrome
###end p 104
###begin p 105
hereditary nonpolyposis colorectal cancer
###end p 105
###begin p 106
microsatellite instability
###end p 106
###begin p 107
microsatellite stable
###end p 107
###begin p 108
tumour necrosis factor
###end p 108
###begin p 109
World Health Organization
###end p 109

